文献速递前列腺癌

STAMPEDE定义的高危前列腺癌患者神经保留机器人辅助根治性前列腺切除术后的肿瘤学与控尿结局

Oncological and continence outcomes after nerve-sparing robot-assisted radical prostatectomy in selected STAMPEDE-defined high-risk prostate cancer.
PubMed 文献 · BJU Int · 2026-09-30

本回顾性单中心队列研究纳入2021至2022年间接受初次机器人辅助根治性前列腺切除术的1385例患者,按STAMPEDE定义的高危因素数量分层,比较神经保留与非神经保留手术的结局。在至少有两个高危因素的患者中,神经保留手术的切缘阳性率、12个月生化复发率及3、12个月控尿率与非神经保留手术相似,但神经保留组12个月时使用的尿垫数量显著更少。

要点

  • 在高危前列腺癌患者中,超过半数可实施神经保留技术。
  • 神经保留未导致短期肿瘤学结局变差。
  • 神经保留组12个月时尿垫使用量显著更少。

核心结论

  • 在结构化患者特异性手术规划路径下,神经保留手术对高危前列腺癌患者可行且不增加短期肿瘤学风险。
  • 神经保留与非神经保留组无尿垫控尿率相似,但神经保留组12个月时尿垫使用量显著更少,提示潜在功能获益。

研究设计与样本

  • 回顾性单中心队列研究,纳入2021至2022年间接受初次机器人辅助根治性前列腺切除术的1385例患者,遵循STROBE声明。
  • 按STAMPEDE定义的高危因素数量将患者分为无、一个、两个及以上三组,并在各风险层内比较神经保留与非神经保留手术的结局。

主要发现

  • 总体神经保留手术比例为75.4%(1044/1385)。
  • 在STAMPEDE定义的高危队列(两个及以上高危标准)中,57.3%(150/262)的患者接受了某种形式的神经保留。
  • 在至少有两个STAMPEDE定义风险因素的患者中,神经保留与非神经保留手术的切缘阳性率(21.3% vs 23.2%,P=0.72)和12个月生化复发率(6.7% vs 5.4%,P=0.9)相似。
  • 上述高危患者中,两组3个月和12个月控尿率也相似(P=0.2和P=0.5),但神经保留组12个月时使用的尿垫数量显著更少(P=0.03)。

临床怎么用

  • 对于经选择的高危前列腺癌患者,在结构化手术规划路径下可考虑神经保留技术,短期肿瘤学结局未显示劣势。
  • 神经保留可能带来减少尿垫使用的功能获益,但需进一步前瞻性评估。

局限性

  • 回顾性单中心设计可能引入选择偏倚。
  • 随访时间较短,仅报告12个月结局。
  • 神经保留策略的获益需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the association between the nerve-sparing (NS) technique applied during radical prostatectomy (RP) and early oncological and continence outcomes in patients with Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)-defined high-risk prostate cancer (PCa) undergoing robot-assisted RP (RARP) within a structured patient-specific surgical planning (PSSP) pathway. PATIENTS AND METHODS: A retrospective single-centre cohort study of 1385 patients who underwent primary RARP between 2021 and 2022 was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Patients were stratified into three groups according to the number of STAMPEDE-defined high-risk factors: none, one, and two or more. Outcomes were compared across these cohorts and between NS- and non-NS (nNS)- RARP, within each risk stratum. RESULTS: Overall, NS-RARP was performed in 75.4% of patients (1044/1385). In the STAMPEDE-defined high-risk cohort (two or more high-risk criteria) 57.3% (150/262) of patients underwent some sort of NS. Among those with at least two STAMPEDE-defined risk factors, oncological outcomes were similar between NS and nNS surgery (positive surgical margin rate 21.3% vs 23.2%, P = 0.72; 12-month biochemical recurrence rate 6.7% vs 5.4%, P = 0.9), and urinary continence rates at 3 and 12 months were also similar (P = 0.2 and P = 0.5, respectively). However, high-risk patients undergoing NS-RARP used significantly fewer pads at 12 months (P = 0.03). CONCLUSION: In a contemporary RARP cohort within a PSSP pathway, NS was feasible in over half of high-risk patients and was not associated with worse short-term oncological outcomes. Although pad-free continence rates were similar between NS and nNS groups, patients undergoing NS-RARP used significantly fewer pads at 12 months, suggesting a potential functional benefit that warrants further prospective evaluation of NS strategies in selected cases.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bilé-Silva A, Rajan P, Lamb B, et al. Oncological and continence outcomes after nerve-sparing robot-assisted radical prostatectomy in selected STAMPEDE-defined high-risk prostate cancer. BJU Int. 2026. PMID: 42817545. doi:10.1111/bju.70460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。